Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PASER vs CAPREOMYCIN SULFATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting translation initiation. Also alters membrane permeability.
Treatment of tuberculosis in combination with other antituberculosis drugs,Off-label: None
Treatment of pulmonary tuberculosis as part of combination therapy,Salvage therapy for multidrug-resistant tuberculosis
4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.
15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.
Terminal elimination half-life is 1.5 to 2.5 hours in patients with normal renal function. In anuria or severe renal impairment (Cr Cl <10 m L/min), half-life may extend to 8-12 hours. Clinical context: Accumulation occurs with renal failure, requiring dose adjustment.
Terminal elimination half-life: 24-40 hours (prolonged in renal impairment; anuria may extend to 96-120 hours).
Hepatic via N-acetyltransferase (polymorphic acetylation); major metabolite is acetyl-PAS.
Not significantly metabolized; primarily excreted unchanged in urine via glomerular filtration.
Renal excretion accounts for approximately 80% of the administered dose, with about 60-70% as unchanged drug and 10-20% as metabolites (primarily acetylated). The remainder is excreted via feces (approximately 10-15%) and minor biliary elimination. Renal clearance is highly dependent on glomerular filtration rate.
Primarily renal (80-90% as unchanged drug via glomerular filtration). Biliary/fecal elimination: <1%.
Protein binding is approximately 10-15%, primarily to albumin. Binding is low, nonlinear, and saturable at high concentrations.
Approximately 30% bound to serum proteins (albumin).
Volume of distribution is 0.5-0.7 L/kg, indicating distribution into total body water. Clinical meaning: Moderate distribution suggests penetration into well-perfused tissues but limited CNS penetration unless inflamed.
0.4-0.6 L/kg (suggests distribution primarily into extracellular fluid; poor CNS penetration unless meninges inflamed).
Oral bioavailability is approximately 70-80% (range 60-90%). Food decreases the rate and extent of absorption, with AUC reduction of about 20-40%.
IM: 100% (only IM route available; no oral formulation).
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 4 g orally every 12 hours; monitor serum concentrations. Use with caution in moderate impairment.
Cr Cl 50-80 m L/min: 15 mg/kg every 24-36 hours; Cr Cl 30-50 m L/min: 15 mg/kg every 48 hours; Cr Cl 10-30 m L/min: 15 mg/kg every 72 hours; Cr Cl <10 m L/min: 15 mg/kg every 96-120 hours.
No specific dose adjustment guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to potential hepatotoxicity; monitor liver function tests.
No dose adjustment required for hepatic impairment; monitor for hepatotoxicity.
Not recommended for children (safety and efficacy not established).
15-30 mg/kg intramuscularly or intravenously once daily (maximum 1 g) for 60 days, then 15-30 mg/kg 2-3 times weekly (maximum 1 g).
Lower initial doses may be considered due to age-related decline in renal function. Monitor renal function and serum concentrations closely.
Initiate at lower end of dosing range; adjust based on renal function due to age-related decline in glomerular filtration rate.
None
None officially listed by FDA; however, use with caution due to potential nephrotoxicity and ototoxicity.
May cause hypothyroidism, hepatitis, and crystalluria. Use with caution in patients with renal impairment or glucose-6-phosphate dehydrogenase deficiency.
Nephrotoxicity: Monitor renal function; risk increases with cumulative dose and concomitant nephrotoxic drugs.,Ototoxicity: Can cause vestibular and cochlear damage, especially in patients with renal impairment.,Neuromuscular blockade: May exacerbate weakness in patients with myasthenia gravis or other neuromuscular disorders.,Electrolyte disturbances: Hypokalemia, hypocalcemia, and hypomagnesemia due to renal tubular effects.
Hypersensitivity to para-aminosalicylic acid or any component; severe renal impairment.
Hypersensitivity to capreomycin or any component,Pre-existing severe renal impairment (Cr Cl < 30 m L/min) unless benefit outweighs risk,Pre-existing hearing loss
Take with food to reduce gastrointestinal irritation. Avoid high-fat meals as they may delay absorption. Avoid alcohol.
No specific food interactions. However, maintain adequate hydration and electrolyte-rich diet (bananas, potatoes) to mitigate hypokalemia.
PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. Second and third trimesters: No known major malformations; risks may include gastrointestinal intolerance in mother. Advised use only if clearly needed.
Animal studies suggest embryotoxicity and teratogenicity; human data limited. Avoid in first trimester; use in second and third trimesters only if clearly needed. Risk of ototoxicity and nephrotoxicity to fetus.
Excreted into breast milk in small amounts. M/P ratio unknown. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for diarrhea or rash.
Small amounts excreted in breast milk; not expected to cause adverse effects in infants due to poor oral absorption. M/P ratio unknown.
No dosing adjustment required for pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) not significant for PASER; standard adult dose of 4 g twice daily is recommended.
No dose adjustment recommended for pregnancy alone; however, concurrent use may require monitoring and adjustment. No pharmacokinetic changes reported.
PASER (aminosalicylic acid) is a second-line antitubercular agent that inhibits folic acid synthesis. Administer with food to reduce GI upset; avoid concurrent use with salicylates due to additive GI irritation. Monitor for hepatotoxicity and hypersensitivity reactions. Drug levels should be monitored in patients with renal impairment.
Capreomycin is a second-line injectable agent for multidrug-resistant tuberculosis (MDR-TB). Monitor for nephrotoxicity (creatinine, BUN) and ototoxicity (audiometry, vestibular testing). Electrolyte disturbances (hypokalemia, hypomagnesemia) are common; replace aggressively. Administer deep IM injection; rotate sites. Contraindicated in pregnancy (teratogenic). Synergistic with other antituberculars; never use as monotherapy.
Take this medication with food to minimize stomach upset.,Do not crush or chew the tablets; swallow them whole.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems (yellowing of skin/eyes, dark urine) or allergic reactions (rash, fever) immediately.,Avoid alcohol during treatment.,Store at room temperature away from moisture and heat.
Take exactly as prescribed; do not skip doses to prevent resistance.,Report hearing loss, ringing in ears, or dizziness immediately.,Report decreased urine output, swelling, or unusual fatigue.,You will need regular blood tests (kidney function, electrolyte levels).,Avoid alcohol and excessive salt intake.,Contact your doctor if you develop severe injection site pain or fever.
No interactions on record
"Decamethonium, a depolarizing neuromuscular blocker, and capreomycin, an aminoglycoside antibiotic, synergistically prolong neuromuscular blockade. Capreomycin decreases acetylcholine release at the motor endplate, while decamethonium persistently depolarizes the postsynaptic membrane, leading to enhanced and prolonged muscle relaxation. This interaction can result in extended respiratory depression and apnea, particularly during anesthesia or in critically ill patients."
"Streptozocin, a nitrosourea alkylating agent, may potentiate the neuromuscular blocking effects of capreomycin, a cyclic polypeptide antibiotic that inhibits neuromuscular transmission by reducing acetylcholine release at the motor endplate. This interaction can lead to prolonged or enhanced muscle weakness, including respiratory depression, particularly in patients with underlying neuromuscular disorders (e.g., myasthenia gravis) or those receiving other neuromuscular blocking agents. The clinical outcome may range from mild skeletal muscle weakness to severe respiratory compromise requiring mechanical ventilation."
"Paromomycin, an aminoglycoside antibiotic, and capreomycin, a polypeptide antibiotic, both possess neuromuscular blocking properties. Their co-administration can result in additive or synergistic neuromuscular blockade, potentially leading to prolonged or enhanced muscle relaxation, respiratory depression, or apnea. This interaction is particularly dangerous in patients receiving general anesthetics, neuromuscular blocking agents, or those with underlying neuromuscular disorders such as myasthenia gravis."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PASER vs CAPREOMYCIN SULFATE, answered by our medical review team.
PASER is a Antitubercular Agent that works by Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.. CAPREOMYCIN SULFATE is a Antitubercular Agent that works by Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of m RNA and inhibiting translation initiation. Also alters membrane permeability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PASER and CAPREOMYCIN SULFATE depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PASER is: 4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.. The standard adult dose of CAPREOMYCIN SULFATE is: 15 mg/kg (up to 1 g) intramuscularly or intravenously once daily for 60 days, then 15 mg/kg (up to 1 g) 2-3 times weekly for 12-18 months in combination with other antituberculosis agents.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PASER and CAPREOMYCIN SULFATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PASER is classified as Category C. PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. CAPREOMYCIN SULFATE is classified as Category C. Animal studies suggest embryotoxicity and teratogenicity; human data limited. Avoid in first trimester; use in second and third trimesters only if clearly needed. Risk of ototoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.